PreDiCT-TB Consortium

Partnership objective

 To find the most rapid and reliable ways of identifying the most potent combinations of new drugs and hasten their ability to be used clinically.

PreDiCT-TB aims to overcome disconnects in TB drug development by adopting a fully integrated multidisciplinary approach. PreDiCT-TB aims to overcome disconnects in TB drug development by adopting a fully integrated multidisciplinary approach. Copyright PreDiCT-TB

What are the health needs and challenges?

Tuberculosis (TB) is an airborne infectious disease caused by Mycobacterium tuberculosis. It usually affects the lungs causing coughing, fever and weight loss. Although the disease has long been both preventable and curable, one person dies from TB somewhere in the world every twenty seconds. Treatment requires six months or more of combinations of antibiotics to ensure complete cure and more effective drugs are urgently needed to shorten treatment. 

Description of partnership activities and how they address needs and challenges:

PreDiCT-TB is a public-private partnership funded by the EU Innovative Medicines Initiative, comprising three major pharmaceutical partners (GSK, Sanofi, and Janssen Pharmaceutical Companies of Johnson & Johnson), two biotechnology firms (ZF Screens and Microsens Medtech) and fifteen academic partners headed by the University of Liverpool. The multidisciplinary consortium brings together experts in microbiology, pharmacology, engineering, mathematical modelling, and clinical trials to create a new integrated framework for TB drug development, making optimal use of preclinical information to design the most efficient clinical trials.

PreDiCT-TB aims to overcome disconnects in TB drug development by adopting a fully integrated multidisciplinary approach grounded in pharmacokinetic (PK) – pharmacodynamic (PD) analysis and calibrated by clinical outcomes. By effectively integrating preclinical information into the early clinical phase, the Consortium aims to provide a new framework and tools that will facilitate the transition of the best combinations of drugs to late phase development and maximise their chances of success.

Summary of impact and forward looking information:

In 2013, Janssen performed a monotherapy PK/PD analysis in a mouse model of tuberculosis infection and a combination PD study combining several first and second line tuberculosis drugs. PreDiCT-TB partners are studying the same drugs and their combinations in other preclinical models.

Partnership information

Company(ies) GlaxoSmithKline , Johnson & Johnson , Sanofi

Partner(s) École Polytechnique Fédérale de Lausanne, Erasmus University, European Commission, European Union, Institute Pasteur, Instituto De Salud Carlos III, Liverpool School of Tropical Medicine, Max Plank Institute, Microsens Medtech, Public Health England, St George's, University of London, Univeristy of St. Andrews, University College London, University of Leicester, University of Liverpool, University of Sussex, Uppsala University, ZF-Screens

Type of Partner(s) Academia / Hospitals, Government, IGOs, Other Business

Therapeutic Focus Infectious Diseases

Disease(s) Tuberculosis

Program Type(s) Research & Development - Development of Treatments

Targeted Population(s) Men, Patients in needs of treatment, People with low income, Women

Region(s) Middle East & North Africa, South Asia, Sub-Saharan Africa

Number of Countries 70

Country(ies) Afghanistan, Algeria, Angola, Bangladesh, Benin, Bhutan, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Djibouti, Egypt, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Ghana, Guinea, Guinea-Bissau, India, Iran, Iraq, Israel, Jordan, Kenya, Lebanon, Lesotho, Liberia, Libya, Madagascar, Malawi, Maldives, Mali, Mauritania, Mauritius, Morocco, Mozambique, Namibia, Nepal, Niger, Nigeria, Pakistan, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sri Lanka, Sudan, Swaziland, Syria, Tanzania, The Gambia, Togo, Tunisia, Uganda, West Bank and Gaza, Yemen, Zambia, Zimbabwe

Start Date 2013

More information PreDiCT-TB Website

Anticipated completion date Ongoing